Month: May 2016

Interview with Dr. Simon Budman, Founder & Chief Strategy Officer at Inflexxion

  We recently spoke with Dr. Simon Budman, an internationally known researcher and innovator, on his thoughts about the challenges around opioid abuse including the significance of routes of administration and the role of generics in the marketplace. Q1: Dr. Budman, what’s the significance of abusers using alternative routes of administration? A: It’s essential to… Read more »

FDA releases steps to ensure safety of abuse-deterrent generic opioids

On March 24, 2016 the Food and Drug Administration (FDA) announced draft guidance for generic versions of approved abuse deterrent formulations (ADF).  The guidance, which is focused on creating policies to address the opioid epidemic, comes out of the action plan that the FDA created in April, 2015 to begin reevaluating the approach to prescription… Read more »

Relative Abuse of ADF Study presented at the American Pain Society Annual Scientific Meeting

A study conducted by scientists at Inflexxion and Collegium Pharmaceuticals was recently presented at the American Pain Society’s 35th Annual Scientific Meeting in Austin, Texas. The study completed by Drs. Butler, Black and Fleming is entitled Relative abuse of abuse deterrent formulations via alternative oral routes. The study examined abuse of prescription opioid products that have been… Read more »

Recently Published: Impact of an Electronic Pain and Opioid Risk Assessment Program: Are There Improvements in Patient Encounters and Clinic Notes?

Recently Published: Impact of an Electronic Pain and Opioid Risk Assessment Program: Are There Improvements in Patient Encounters and Clinic Notes? The American Academy of Pain Medicine recently published an article by researchers at Inflexxion Inc., Newton-Wellesley Hospital’s Pain Management Center, Brigham and Women’s Hospital Pain Management Center, and at the University of Mississippi Medical Center,… Read more »

Assessing Abuse Deterrence for New and Low Market Share Products: The absence of evidence is not the evidence of absence

In March, Inflexxion’s Founder and Chief Strategy Officer, Simon Budman, presented at the Abuse Deterrent Formulation Summit.  The presentation, titled “Assessing Abuse Deterrence for New and Low Market Share Products:  The absence of evidence is not the evidence of absence,” gave an in-depth look at a number of innovative approaches and novel data streams used… Read more »